about
New endoscopic ultrasonography techniques for pancreaticobiliary diseases.JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of JapanAntiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferonGuidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUSTherapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinomaHepatocellular Carcinoma: Therapeutic Guidelines and Medical TreatmentGuidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUSReactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesisContrast-enhanced harmonic endoscopic ultrasonography for assessment of lymph node metastases in pancreatobiliary carcinoma.Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations.Imaging findings of biliary hamartomas.Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma.Diagnosis of pancreatic tumors by endoscopic ultrasonography.Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cm.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonographyNoninvasive diagnosis of liver fibrosis: utility of data mining of both ultrasound elastography and serological findings to construct a decision tree.Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.Autoimmune thrombocytopenic purpura during pegylated interferon α treatment for chronic hepatitis C.Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma.A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma.Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-FluorouracilA novel biomarker TERTmRNA is applicable for early detection of hepatoma.Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancerCronkhite-Canada syndrome associated with triple gastric cancers: a case report.Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.Hepatocellular carcinoma metastasizing to the skull base involving multiple cranial nerves.Identifying and prioritizing strategies for comprehensive liver cancer control in Asia.Well-to moderately-differentiated HCC manifesting hyperattenuation on both CT during arteriography and arterial portography.NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6.Diagnosis of subepithelial tumors in the upper gastrointestinal tract by endoscopic ultrasonography.Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score.Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
P50
Q26746663-91C5C2B7-E82E-45CE-8942-C56F151BD12AQ26797521-130875B1-A433-46D7-B8F0-4290A8E12FDFQ26830435-EF62BF6F-2EEB-493F-977E-313CDEA6D402Q26997111-96CA4A72-A03D-44D4-A2EB-7B10B1F834F2Q27016138-8DA8DD09-D1ED-4E44-B90D-FFF906D67123Q27851797-CBEEECAF-4403-48D8-9314-D8096F817339Q28079378-B08562EA-FCA1-4347-A715-6645947EA6ACQ28278903-5A29D01D-E9A9-49A3-AF97-F864B14055EEQ28302853-B657134D-49C8-4D4C-AF4B-655EEC0E51CCQ30387535-48916EE6-C9D0-44EE-B13E-19F43CCD7114Q30394196-24968920-E51E-42B6-B68D-02D70679BF94Q30419051-87439498-65DE-40DB-BB51-F31DD2046E6CQ30472126-947028D1-E0BC-4C3C-899F-BAA12660EB2BQ30478151-35E91582-19FD-4E6C-A381-D8D60B0141F3Q30479583-55FB42F1-1A48-43C4-88B9-C7EA322E6DC6Q30479629-F1BBCAAE-F4C1-4326-99C3-05F2DFD4AE1EQ30542675-B5A8FA14-DF9A-4C69-8452-5F0BDB4AFF59Q30872132-BA344A3C-6BC5-481F-82C4-87F2A1DB335BQ33382489-48253D9D-AB0D-4227-B0E1-D56DA2055510Q33383179-020B3E60-97F3-4FE5-B693-4CBB8281B37DQ33390225-55B32952-31C1-4B84-85ED-A223CD4C8AF1Q33390589-EDE7F93C-9029-498B-807A-DEBDC1EB132DQ33392300-D6BA89C6-0D91-45CE-9697-598F4992615AQ33398836-C5857AFB-6C2F-4305-A4F1-0A020C79F781Q33410643-2F23052B-A6B9-4A25-9499-3044FF3043F6Q33423800-5C2C99DC-21D0-4FDA-9D9A-C9359D8BC82DQ33428936-B4516D5B-7713-44A3-9460-202190D371A2Q33581156-1046709A-E8F7-44F1-8918-FEA993CC4CE7Q33718622-826C24FC-4010-4455-8576-B30D9199DB92Q33760426-C61E6CB7-83B3-436B-B6EB-37C132F1FCE6Q33829431-FEF62385-8E8D-4E92-BD0B-76DEF22ABE61Q34001687-E67C49BB-4B32-429E-8C77-4EA4E7CE94EAQ34017826-5015A549-68EE-4806-A666-9E475909F09DQ34065382-0A902ADD-2405-4F0B-8032-76BAD90E8A31Q34225427-47F2296B-B408-424E-A1AA-3BE4ED2404D4Q34253078-9EC25E86-DA0B-4986-93B7-1F82840F2B72Q34389788-915029EA-9C23-498E-901E-E9CA0080DE4FQ34602130-C1A5B431-01DE-4761-897F-53B393687710Q34647911-90ECB01F-74DB-4209-8172-C2EDEAA48918Q34663499-292AE555-C5EF-414B-A048-857C4215BD88
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Masatoshi Kudo
@ast
Masatoshi Kudo
@de
Masatoshi Kudo
@en
Masatoshi Kudo
@es
Masatoshi Kudo
@sl
type
label
Masatoshi Kudo
@ast
Masatoshi Kudo
@de
Masatoshi Kudo
@en
Masatoshi Kudo
@es
Masatoshi Kudo
@sl
prefLabel
Masatoshi Kudo
@ast
Masatoshi Kudo
@de
Masatoshi Kudo
@en
Masatoshi Kudo
@es
Masatoshi Kudo
@sl
P214
P227
P244
P1153
55216757300
P213
0000 0000 1935 2760
P214
P227
P244
no2002088759
P31
P496
0000-0002-4102-3474
P734
P735
P7859
lccn-no2002088759